In conclusion, we have demonstrated that anagliptin prevents fibrogenesis and carcinogenesis in the liver of MC4R-KO mice fed WD, but only marginally affecting body weight, systemic glucose and lipid metabolism, and hepatic steatosis. Here, MC4R is linked to fatty liver disease.